JP2013531477A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013531477A5 JP2013531477A5 JP2013509178A JP2013509178A JP2013531477A5 JP 2013531477 A5 JP2013531477 A5 JP 2013531477A5 JP 2013509178 A JP2013509178 A JP 2013509178A JP 2013509178 A JP2013509178 A JP 2013509178A JP 2013531477 A5 JP2013531477 A5 JP 2013531477A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- polypeptide
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical class 0.000 claims 36
- 229920001184 polypeptide Polymers 0.000 claims 32
- 102000007562 Serum Albumin Human genes 0.000 claims 5
- 108010071390 Serum Albumin Proteins 0.000 claims 5
- 230000004927 fusion Effects 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102100008658 FN1 Human genes 0.000 claims 2
- 102000002090 Fibronectin type III Human genes 0.000 claims 2
- 108050009401 Fibronectin type III Proteins 0.000 claims 2
- 108010067306 Fibronectins Proteins 0.000 claims 2
- 230000036499 Half live Effects 0.000 claims 2
- 210000002966 Serum Anatomy 0.000 claims 2
- 230000037320 fibronectin Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102100001249 ALB Human genes 0.000 claims 1
- 101710027066 ALB Proteins 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006822 Human Serum Albumin Proteins 0.000 claims 1
- 241000282560 Macaca mulatta Species 0.000 claims 1
- 229940050528 albumin Drugs 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 102000003973 fibroblast growth factor 21 Human genes 0.000 claims 1
- 108090000376 fibroblast growth factor 21 Proteins 0.000 claims 1
- 102000037240 fusion proteins Human genes 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33067210P | 2010-05-03 | 2010-05-03 | |
| US61/330,672 | 2010-05-03 | ||
| US13/098,851 | 2011-05-02 | ||
| US13/098,851 US8969289B2 (en) | 2010-05-03 | 2011-05-02 | Serum albumin binding molecules |
| PCT/US2011/034998 WO2011140086A2 (en) | 2010-05-03 | 2011-05-03 | Serum albumin binding molecules |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015210912A Division JP6219357B2 (ja) | 2010-05-03 | 2015-10-27 | 血清アルブミン結合性分子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013531477A JP2013531477A (ja) | 2013-08-08 |
| JP2013531477A5 true JP2013531477A5 (ru) | 2014-06-19 |
| JP5876872B2 JP5876872B2 (ja) | 2016-03-02 |
Family
ID=44628186
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013509178A Expired - Fee Related JP5876872B2 (ja) | 2010-05-03 | 2011-05-03 | 血清アルブミン結合性分子 |
| JP2015210912A Expired - Fee Related JP6219357B2 (ja) | 2010-05-03 | 2015-10-27 | 血清アルブミン結合性分子 |
| JP2017185708A Pending JP2018057368A (ja) | 2010-05-03 | 2017-09-27 | 血清アルブミン結合性分子 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015210912A Expired - Fee Related JP6219357B2 (ja) | 2010-05-03 | 2015-10-27 | 血清アルブミン結合性分子 |
| JP2017185708A Pending JP2018057368A (ja) | 2010-05-03 | 2017-09-27 | 血清アルブミン結合性分子 |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US8969289B2 (ru) |
| EP (1) | EP2566888A2 (ru) |
| JP (3) | JP5876872B2 (ru) |
| KR (1) | KR101854931B1 (ru) |
| CN (2) | CN107698682A (ru) |
| AR (1) | AR081459A1 (ru) |
| AU (1) | AU2011248273B2 (ru) |
| BR (1) | BR112012028162A2 (ru) |
| CA (1) | CA2798510A1 (ru) |
| CL (1) | CL2012003077A1 (ru) |
| CO (1) | CO6630173A2 (ru) |
| EA (1) | EA029334B1 (ru) |
| IL (1) | IL222832A0 (ru) |
| MX (2) | MX346557B (ru) |
| PE (1) | PE20130593A1 (ru) |
| SG (2) | SG10201503366XA (ru) |
| TN (1) | TN2012000518A1 (ru) |
| TW (1) | TW201138808A (ru) |
| UY (1) | UY33366A (ru) |
| WO (1) | WO2011140086A2 (ru) |
| ZA (1) | ZA201209091B (ru) |
Families Citing this family (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5006651B2 (ja) | 2003-12-05 | 2012-08-22 | ブリストル−マイヤーズ スクウィブ カンパニー | ２型血管内皮増殖因子受容体の阻害剤 |
| US8673848B2 (en) | 2012-01-27 | 2014-03-18 | Novartis Ag | Synthetic apelin mimetics for the treatment of heart failure |
| EP2727936B1 (en) | 2006-11-22 | 2016-09-07 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR |
| BRPI0809583B1 (pt) | 2007-03-30 | 2022-02-22 | Ambrx, Inc | Polipeptídeo fgf-21 modificado, composição compreendendo o mesmo, método para produzir o referido polipetídeo fgf-21 e célula compreendendo um polinucleotídeo |
| WO2009102421A2 (en) | 2008-02-14 | 2009-08-20 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind egfr |
| EP2291399B1 (en) | 2008-05-22 | 2014-06-25 | Bristol-Myers Squibb Company | Multivalent fibronectin based scaffold domain proteins |
| EP4074327A1 (en) * | 2008-06-27 | 2022-10-19 | Duke University | Therapeutic agents comprising elastin-like peptides |
| TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子 |
| TW201138808A (en) | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
| EP2576615B1 (en) | 2010-05-26 | 2016-03-30 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
| US9139629B2 (en) | 2010-06-05 | 2015-09-22 | The Uab Research Foundation | Methods for treatment of nephrotic syndrome and related conditions |
| US9475850B2 (en) * | 2010-06-05 | 2016-10-25 | The Uab Research Foundation | Methods for treatment of nephrotic syndrome and related conditions |
| WO2012116264A1 (en) | 2011-02-24 | 2012-08-30 | The Trustees Of The University Of Pennsylvania | Biomarkers for seizures |
| US9403891B2 (en) * | 2011-03-10 | 2016-08-02 | New York University | Methods and compositions for modulating TNF/TNFR signaling |
| ES2942455T3 (es) | 2011-04-13 | 2023-06-01 | Bristol Myers Squibb Co | Proteínas de fusión Fc que comprenden enlazadores o disposiciones nuevos |
| EP2710382B1 (en) | 2011-05-17 | 2017-10-18 | Bristol-Myers Squibb Company | Improved methods for the selection of binding proteins |
| US20140187488A1 (en) | 2011-05-17 | 2014-07-03 | Bristol-Myers Squibb Company | Methods for maintaining pegylation of polypeptides |
| US9382304B2 (en) * | 2011-07-08 | 2016-07-05 | Amylin Pharmaceuticals, Llc | Engineered polypeptides having enhanced duration of action with reduced immunogenicity |
| US9522951B2 (en) | 2011-10-31 | 2016-12-20 | Bristol-Myers Squibb Company | Fibronectin binding domains with reduced immunogenicity |
| GB2503131B (en) | 2012-02-21 | 2015-11-18 | Cytonics Corp | Systems, compositions and methods for transplantation |
| LT3564258T (lt) | 2012-09-13 | 2021-08-25 | Bristol-Myers Squibb Company | Karkasiniai domeniniai baltymai fibronektino pagrindu, kurie jungiasi su miostatinu |
| UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
| US8921307B2 (en) | 2012-11-20 | 2014-12-30 | Novartis Ag | Synthetic linear apelin mimetics for the treatment of heart failure |
| WO2014100913A1 (en) * | 2012-12-24 | 2014-07-03 | Beijing Anxinhuaide Biotech. Co., Ltd | Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer |
| US20150361159A1 (en) | 2013-02-01 | 2015-12-17 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins |
| EP2953968B1 (en) | 2013-02-06 | 2018-07-25 | Bristol-Myers Squibb Company | Fibronectin type iii domain proteins with enhanced solubility |
| ES2870802T3 (es) | 2013-02-12 | 2021-10-27 | Bristol Myers Squibb Co | Métodos de replegado de proteínas a elevado pH |
| EP2968587A2 (en) | 2013-03-13 | 2016-01-20 | Bristol-Myers Squibb Company | Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto |
| WO2014152955A1 (en) | 2013-03-14 | 2014-09-25 | Regeneron Pharmaceuticals, Inc. | Apelin fusion proteins and uses thereof |
| CN103333255A (zh) * | 2013-06-28 | 2013-10-02 | 复旦大学 | 一种长效hiv‐1膜融合抑制剂 |
| CA2918077A1 (en) | 2013-07-25 | 2015-01-29 | Novartis Ag | Bioconjugates of synthetic apelin polypeptides |
| MX2016001020A (es) | 2013-07-25 | 2016-08-03 | Novartis Ag | Polipeptidos ciclicos para el tratamiento de insuficiencia cardiaca. |
| CN103550790B (zh) * | 2013-11-04 | 2016-01-27 | 上海交通大学医学院附属瑞金医院 | 骨膜蛋白抗体及其在药物制备中的应用 |
| MX2016006709A (es) | 2013-11-20 | 2016-09-08 | Regeneron Pharma | Moduladores de aplnr y usos de estos. |
| ES2913840T3 (es) * | 2014-03-20 | 2022-06-06 | Bristol Myers Squibb Co | Dominios de tipo III de fibronectina de unión a seroalbúmina |
| AR099856A1 (es) * | 2014-03-27 | 2016-08-24 | Genentech Inc | Métodos para diagnosticar y tratar la enfermedad de intestino inflamado |
| WO2016065326A2 (en) | 2014-10-24 | 2016-04-28 | Bristol-Myers Squibb Company | Modified fgf-21 polypeptides and uses thereof |
| ES2807182T3 (es) | 2014-11-21 | 2021-02-22 | Bristol Myers Squibb Co | Anticuerpos frente a CD73 y sus usos |
| JP6701217B2 (ja) | 2014-11-25 | 2020-05-27 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 生物学的製剤の１８ｆ−放射性標識方法および組成物 |
| EP3702367B1 (en) | 2014-11-25 | 2024-05-15 | Bristol-Myers Squibb Company | Novel pd-l1 binding polypeptides for imaging |
| CN104587457B (zh) * | 2015-01-13 | 2017-03-22 | 广东海大畜牧兽医研究院有限公司 | 一种利用难溶或不溶蛋白、多肽抗原制备纳米微粒疫苗的方法 |
| BR112017014194A2 (pt) | 2015-01-23 | 2018-01-09 | Novartis Ag | conjugados de ácido graxo de apelina sintéticos com meia-vida melhorada |
| WO2016164608A1 (en) * | 2015-04-07 | 2016-10-13 | Alector Llc | Methods of screening for sortilin binding antagonists |
| MX2017013687A (es) * | 2015-04-24 | 2018-07-06 | Viiv Healthcare Uk No 5 Ltd | Polipeptidos dirigidos a la fusion de vih. |
| JP7284557B2 (ja) * | 2015-06-12 | 2023-05-31 | マッカイ メディカル ファンデーション ザ プレスビュテロス チャーチ イン タイワン マッカイ メモリアル ホスピタル | 医薬組成物 |
| WO2017024137A1 (en) * | 2015-08-04 | 2017-02-09 | New York University | Progranulin (pgrn) fragments and derivatives for treatment or alleviation of lysosomal storage diseases |
| ES2781207T3 (es) * | 2015-09-23 | 2020-08-31 | Bristol Myers Squibb Co | Dominios de fibronectina de tipo iii de unión a seroalbúmina con velocidad de disociación rápida |
| EP3442997A2 (en) * | 2016-04-15 | 2019-02-20 | Indiana University Research & Technology Corporation | Fgf21 c-terminal peptide optimization |
| US10994033B2 (en) | 2016-06-01 | 2021-05-04 | Bristol-Myers Squibb Company | Imaging methods using 18F-radiolabeled biologics |
| CN109562195A (zh) | 2016-06-01 | 2019-04-02 | 百时美施贵宝公司 | 用pd-l1结合多肽进行pet成像 |
| JP7111627B2 (ja) | 2016-06-03 | 2022-08-02 | ヤンセン バイオテツク，インコーポレーテツド | 血清アルブミン結合フィブロネクチンｉｉｉ型ドメイン |
| CN106110325A (zh) * | 2016-06-08 | 2016-11-16 | 上海朗安生物技术有限公司 | 一种新型 glp‑1 受体激动剂的制备方法及其在神经退行性疾病治疗领域的应用 |
| MA45412A (fr) * | 2016-06-21 | 2021-05-26 | Janssen Biotech Inc | Molécules de liaison au domaine de fibronectine de type iii modifiées par la cystéine |
| CN107693775A (zh) * | 2016-08-08 | 2018-02-16 | 中国人民解放军沈阳军区总医院 | Creg蛋白用于预防或治疗体重超重、肥胖及其相关疾病的医药用途 |
| WO2018052828A1 (en) * | 2016-09-14 | 2018-03-22 | Janssen Biotech, Inc. | Chimeric antigen receptors comprising bcma-specific fibronectin type iii domains and uses thereof |
| US11248022B2 (en) | 2017-03-08 | 2022-02-15 | The Regents Of The University Of Michigan | Glypican-3 peptide reagents and methods |
| KR102432962B1 (ko) | 2017-03-16 | 2022-08-12 | 쉔첸 인스티튜트스 오브 어드밴스드 테크놀로지 | 에너지 대사를 조절하는 폴리펩티드 및 그 용도 |
| WO2018165933A1 (zh) * | 2017-03-16 | 2018-09-20 | 深圳先进技术研究院 | 调节糖代谢的多肽及其用途 |
| GB201710973D0 (en) | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
| CN111201246B (zh) * | 2017-07-11 | 2023-10-27 | 亚力兄制药公司 | 结合补体成分c5或血清白蛋白的多肽及其融合蛋白 |
| CN109957005B (zh) * | 2017-12-22 | 2021-04-20 | 深圳先进技术研究院 | 一种代谢素多肽人工抗原及其制备方法、抗体以及应用 |
| CN109957006B (zh) * | 2017-12-22 | 2021-04-20 | 深圳先进技术研究院 | 一种代谢素多肽人工抗原以及抗体和应用 |
| US20210230242A1 (en) * | 2018-06-18 | 2021-07-29 | Anwita Biosciences, Inc. | Cytokine fusion proteins and uses thereof |
| WO2020085766A1 (ko) * | 2018-10-24 | 2020-04-30 | 한국과학기술원 | 인간 혈장 알부민에 특이적으로 결합하는 신규한 폴리펩티드 및 이의 용도 |
| CA3097443A1 (en) * | 2018-11-12 | 2020-05-22 | I-Mab Biopharma Us Limited | Fusion proteins containing cd47 antibodies and cytokines |
| CN109821012A (zh) * | 2019-04-08 | 2019-05-31 | 河南师范大学 | 一种用于治疗代谢疾病的药物组合物及其缓释微球制剂 |
| TWI844709B (zh) * | 2019-07-31 | 2024-06-11 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| TW202128775A (zh) | 2019-10-16 | 2021-08-01 | 英商阿法克塔生命科學有限公司 | PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分 |
| CN111965356B (zh) * | 2019-11-28 | 2023-09-08 | 上海荣盛生物药业股份有限公司 | 巯基还原组合物及荧光微球层析试纸和应用 |
| CN113092772A (zh) * | 2019-12-23 | 2021-07-09 | 首都医科大学附属北京世纪坛医院 | 尿液黏连蛋白亚组sa-2及其多肽片段在过敏性疾病中的应用 |
| CN111521812B (zh) * | 2019-12-25 | 2023-02-17 | 瑞博奥(广州)生物科技股份有限公司 | 视神经脊髓炎谱系疾病生物标记物组及其应用和蛋白芯片、试剂盒 |
| CN113728013B (zh) | 2020-01-11 | 2022-06-14 | 北京质肽生物医药科技有限公司 | Glp-1和fgf21的融合蛋白的缀合物 |
| CN112694526B (zh) * | 2020-05-27 | 2023-01-20 | 杭州先为达生物科技有限公司 | 一种白细胞介素29突变体蛋白 |
| WO2021238302A1 (zh) * | 2020-05-27 | 2021-12-02 | 杭州先为达生物科技有限公司 | 一种白细胞介素29突变体蛋白 |
| GB202101299D0 (en) | 2020-06-09 | 2021-03-17 | Avacta Life Sciences Ltd | Diagnostic polypetides and methods |
| CN114075272B (zh) * | 2020-08-10 | 2023-09-22 | 杭州俊丰生物工程有限公司 | 一种人神经调节蛋白4的制备方法 |
| CN111983241B (zh) * | 2020-09-04 | 2022-05-20 | 四川大学华西医院 | 诊断脑卒中认知障碍的蛋白标志物以及模型的训练方法 |
| CN112321720A (zh) * | 2020-11-05 | 2021-02-05 | 无锡和邦生物科技有限公司 | 一种艾塞那肽人血清白蛋白融合蛋白的纯化方法 |
| CN114848795B (zh) * | 2021-02-03 | 2023-04-14 | 四川大学 | RORa蛋白及其激动剂在制备抗衰老药物中的应用 |
| CN112870336B (zh) * | 2021-02-24 | 2022-06-14 | 杭州先为达生物科技有限公司 | 一种白细胞介素29突变体蛋白制剂 |
| WO2022234003A1 (en) | 2021-05-07 | 2022-11-10 | Avacta Life Sciences Limited | Cd33 binding polypeptides with stefin a protein |
| EP4288461A1 (en) * | 2021-07-14 | 2023-12-13 | Beijing QL Biopharmaceutical Co., Ltd. | Fusion polypeptides for metabolic disorders |
| WO2023057567A1 (en) | 2021-10-07 | 2023-04-13 | Avacta Life Sciences Limited | Pd-l1 binding affimers |
| TW202332694A (zh) | 2021-10-07 | 2023-08-16 | 英商阿凡克塔生命科學公司 | 血清半衰期延長之ｐｄ－ｌ１結合多肽 |
| CN114288414A (zh) * | 2021-12-07 | 2022-04-08 | 深圳先进技术研究院 | 一种跨血脑屏障的多肽及其衍生物和应用 |
| CN114306630A (zh) * | 2021-12-07 | 2022-04-12 | 深圳先进技术研究院 | 一种靶向脑瘤的多肽及其衍生物和应用 |
| WO2023153876A1 (ko) | 2022-02-10 | 2023-08-17 | 주식회사 아피셀테라퓨틱스 | Cd40l에 특이적으로 결합하는 스테핀 a 단백질 변이체 및 이의 용도 |
| WO2023183932A2 (en) * | 2022-03-25 | 2023-09-28 | New York University | Monobodies binding to intercellular adhesion molecule 2 (icam-2) |
| CN114432429A (zh) * | 2022-04-12 | 2022-05-06 | 中国人民解放军军事科学院军事医学研究院 | 一种预防或治疗骨关节炎的活性分子及其应用 |
| WO2023218243A1 (en) | 2022-05-12 | 2023-11-16 | Avacta Life Sciences Limited | Lag-3/pd-l1 binding fusion proteins |
| CN117645661A (zh) * | 2022-09-02 | 2024-03-05 | 北京志道生物科技有限公司 | 一种聚乙二醇修饰的il-21衍生物及其应用 |
| WO2024051796A1 (en) * | 2022-09-09 | 2024-03-14 | Wuxi Biologics (Shanghai) Co., Ltd. | Albumin binding proteins, fusion proteins and uses thereof |
| CN115433776B (zh) * | 2022-09-30 | 2023-12-22 | 中国医学科学院阜外医院 | Ccn3在调控血管平滑肌细胞钙化中的应用 |
| CN115724951B (zh) * | 2022-11-15 | 2023-10-03 | 怡道生物科技(苏州)有限公司 | 与11型hpv结合的抗体或其抗原结合片段及其应用 |
| WO2024153195A1 (en) * | 2023-01-18 | 2024-07-25 | Beijing Ql Biopharmaceutical Co., Ltd. | Liquid pharmaceutical compositions of fusion polypeptides and methods of uses thereof |
| WO2024168325A2 (en) * | 2023-02-10 | 2024-08-15 | Biohaven Therapeutics Ltd. | Administration of fibronectin based scaffold domain proteins totreat overweight, obesity, and related health conditions |
| FR3147292A1 (fr) | 2023-03-31 | 2024-10-04 | Affyxell Therapeutics Co., Ltd. | Cellules genetiquement modifiees dans lesquelles un acide nucleique codant pour des variantes de la proteine stefine a se liant specifiquement au tnfr2 ou une proteine de fusion comprenant celle-ci a ete introduite, et leurs utilisations |
| WO2024200987A1 (en) | 2023-03-31 | 2024-10-03 | Avacta Life Sciences Limited | Tnfr2 binding polypeptides and methods of use |
| FR3147278A1 (fr) | 2023-03-31 | 2024-10-04 | Avacta Life Sciences Limited | Polypeptides de liaison au tnfr2 et procedes d'utilisation |
Family Cites Families (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4708934A (en) | 1984-09-27 | 1987-11-24 | Unigene Laboratories, Inc. | α-amidation enzyme |
| US6319685B1 (en) | 1984-09-27 | 2001-11-20 | Unigene Laboratories, Inc. | Alpha-amidating enzyme compositions and processes for their production and use |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
| US5770697A (en) | 1986-11-04 | 1998-06-23 | Protein Polymer Technologies, Inc. | Peptides comprising repetitive units of amino acids and DNA sequences encoding the same |
| US6018030A (en) | 1986-11-04 | 2000-01-25 | Protein Polymer Technologies, Inc. | Peptides comprising repetitive units of amino acids and DNA sequences encoding the same |
| US5641648A (en) | 1986-11-04 | 1997-06-24 | Protein Polymer Technologies, Inc. | Methods for preparing synthetic repetitive DNA |
| US5514581A (en) | 1986-11-04 | 1996-05-07 | Protein Polymer Technologies, Inc. | Functional recombinantly prepared synthetic protein polymer |
| US5367052A (en) | 1987-04-27 | 1994-11-22 | Amylin Pharmaceuticals, Inc. | Amylin peptides |
| US5789234A (en) | 1987-08-14 | 1998-08-04 | Unigene Laboratories, Inc. | Expression systems for amidating enzyme |
| EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| AU8498091A (en) | 1990-08-02 | 1992-03-02 | Regents Of The University Of Colorado, The | Systematic polypeptide evolution by reverse translation |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| US5773574A (en) | 1990-12-03 | 1998-06-30 | The Scripps Research Institute | Polypeptides for promoting cell attachment |
| US5235041A (en) | 1990-12-28 | 1993-08-10 | Protein Polymer Technologies, Inc. | Purification of structurally ordered recombinant protein polymers |
| HU222249B1 (hu) | 1991-03-08 | 2003-05-28 | Amylin Pharmaceuticals Inc. | Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására |
| US5792742A (en) | 1991-06-14 | 1998-08-11 | New York University | Fibrin-binding peptide fragments of fibronectin |
| DE69228118T2 (de) | 1991-06-25 | 1999-08-19 | Genetics Institute | Bmp-9 zusammensetzungen |
| US6287816B1 (en) | 1991-06-25 | 2001-09-11 | Genetics Institute, Inc. | BMP-9 compositions |
| AU2313392A (en) | 1991-08-01 | 1993-03-02 | University Research Corporation | Systematic polypeptide evolution by reverse translation |
| DE69329503T2 (de) | 1992-11-13 | 2001-05-03 | Idec Pharma Corp | Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma |
| WO1994017097A1 (en) | 1993-01-19 | 1994-08-04 | Regents Of The University Of Minnesota | Synthetic fibronectin fragments as inhibitors of retroviral infections |
| EP0692971A4 (en) | 1993-03-29 | 1997-11-12 | Univ Cincinnati | PEPTIDE YY ANALOGS AND USES THEREOF |
| AU8124694A (en) | 1993-10-29 | 1995-05-22 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
| US5559000A (en) | 1995-01-18 | 1996-09-24 | The Scripps Research Institute | Encoded reaction cassette |
| DE19646372C1 (de) | 1995-11-11 | 1997-06-19 | Evotec Biosystems Gmbh | Genotyp und Phänotyp koppelnde Verbindung |
| GB9618960D0 (en) | 1996-09-11 | 1996-10-23 | Medical Science Sys Inc | Proteases |
| US5922676A (en) | 1996-09-20 | 1999-07-13 | The Burnham Institute | Methods of inhibiting cancer by using superfibronectin |
| WO1998016636A1 (fr) | 1996-10-17 | 1998-04-23 | Mitsubishi Chemical Corporation | Molecule permettant d'homologuer un genotype et un phenotype, et utilisation de celle-ci |
| WO1998031700A1 (en) | 1997-01-21 | 1998-07-23 | The General Hospital Corporation | Selection of proteins using rna-protein fusions |
| US6261804B1 (en) | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
| US5830434A (en) | 1997-02-26 | 1998-11-03 | Medical University Of South Carolina Foundation For Research Development | Methods of treating non-insulin dependent diabetes mellitus with pancreatic polypeptide |
| AU7266898A (en) | 1997-04-30 | 1998-11-24 | Enzon, Inc. | Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof |
| DK0985039T3 (da) | 1997-06-12 | 2008-06-09 | Novartis Int Pharm Ltd | Kunstige antistof-polypeptider |
| US6159722A (en) | 1997-12-03 | 2000-12-12 | Boehringer Mannheim Gmbh | Chimeric serine proteases |
| US6046167A (en) | 1998-03-25 | 2000-04-04 | University Of Cincinnati | Peptide YY analogs |
| IL138668A0 (en) | 1998-04-03 | 2001-10-31 | Phylos Inc | Addressable protein arrays |
| CA2342967A1 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Modifying protein immunogenicity |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| CA2351346C (en) | 1998-12-10 | 2015-09-01 | Phylos, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| GB9827228D0 (en) | 1998-12-10 | 1999-02-03 | Univ Nottingham | Cancer detection method and reagents |
| US6307024B1 (en) | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
| DE60011612T2 (de) | 1999-04-28 | 2005-07-07 | Board of Regents, The University of Texas System, Austin | Zusammensetzungen und Verfahren zur Krebsbehandlung durch die selektive Hemmung von VEGF |
| US7601691B2 (en) | 1999-05-17 | 2009-10-13 | Conjuchem Biotechnologies Inc. | Anti-obesity agents |
| ATE360706T1 (de) | 1999-07-27 | 2007-05-15 | Adnexus Therapeutics Inc | Peptidakzeptor ligationsverfahren |
| AU4445601A (en) | 2000-03-31 | 2001-10-08 | Centre National De La Recherche Scientifique-Cnrs | Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof |
| JP2004515219A (ja) | 2000-06-15 | 2004-05-27 | ボード・オブ・リージェンツ，ザ・ユニヴァーシティ・オヴ・テキサス・システム | 調節可能な触媒活性な核酸 |
| JP4578768B2 (ja) | 2000-07-11 | 2010-11-10 | リサーチ コーポレイション テクノロジーズ，インコーポレイテッド | 人工抗体ポリペプチド |
| JP2004526419A (ja) | 2000-10-16 | 2004-09-02 | フィロス インク． | 抗体模倣物および他の結合タンパク質のためのタンパク質骨格 |
| US7598352B2 (en) | 2000-11-17 | 2009-10-06 | University Of Rochester | Method of identifying polypeptide monobodies which bind to target proteins and use thereof |
| US7556925B2 (en) | 2001-04-04 | 2009-07-07 | University Of Rochester | ανβ3 integrin-binding polypeptide monobodies and their use |
| WO2002088171A2 (en) | 2001-04-26 | 2002-11-07 | Avidia Research Institute | Combinatorial libraries of monomer domains |
| WO2003022858A2 (de) | 2001-09-11 | 2003-03-20 | Nascacell Gmbh | Verfahren zum screenen von inhibitoren für die protein-protein-wechselwirkung sowie ribozyme hierzu |
| US20080193445A1 (en) | 2002-01-18 | 2008-08-14 | Liliane Goetsch | Novel anti-IGF-IR antibodies and uses thereof |
| AU2003243436A1 (en) | 2002-06-06 | 2003-12-22 | Shohei Koide | Reconstituted polypeptides |
| DE10227232A1 (de) | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
| US7135170B2 (en) | 2002-10-23 | 2006-11-14 | Zymogenetics, Inc. | Methods for treating viral infection using IL-28 and IL-29 |
| US20080220049A1 (en) | 2003-12-05 | 2008-09-11 | Adnexus, A Bristol-Myers Squibb R&D Company | Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins |
| JP5006651B2 (ja) | 2003-12-05 | 2012-08-22 | ブリストル−マイヤーズ スクウィブ カンパニー | ２型血管内皮増殖因子受容体の阻害剤 |
| WO2006020258A2 (en) | 2004-07-17 | 2006-02-23 | Imclone Systems Incorporated | Novel tetravalent bispecific antibody |
| US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
| FR2888850B1 (fr) | 2005-07-22 | 2013-01-11 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| WO2007044688A1 (en) | 2005-10-07 | 2007-04-19 | The Regents Of The University Of California | Nucleic acids encoding modified cytochrome p450 enzymes and methods of use thereof |
| KR20180030264A (ko) | 2005-11-23 | 2018-03-21 | 악셀레론 파마 인코포레이티드 | 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도 |
| KR20080097188A (ko) | 2006-02-24 | 2008-11-04 | 키에시 파르마슈티시 엣스. 피. 에이. | 항아밀로이드 면역성성분, 그 제조방법 및 용도 |
| WO2007121894A2 (en) | 2006-04-21 | 2007-11-01 | Transgene S.A. | Hpv-18-based papillomavirus vaccine |
| WO2008031098A1 (en) | 2006-09-09 | 2008-03-13 | The University Of Chicago | Binary amino acid libraries for fibronectin type iii polypeptide monobodies |
| CA2666507A1 (en) | 2006-10-16 | 2008-04-24 | The Arizona Board Of Regents, A Body Corporate Of The State Of Arizona A Cting For And On Behalf Of Arizona State University | Synthetic antibodies |
| EP2727936B1 (en) * | 2006-11-22 | 2016-09-07 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR |
| ATE516814T1 (de) | 2007-02-02 | 2011-08-15 | Bristol Myers Squibb Co | 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese |
| CA2679548C (en) | 2007-03-02 | 2015-01-27 | Amgen Inc. | Methods and compositions for treating tumor diseases |
| US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
| EP2222846B1 (en) | 2007-08-10 | 2017-05-03 | Protelix, Inc. | Universal fibronectin type iii binding-domain libraries |
| US8680019B2 (en) | 2007-08-10 | 2014-03-25 | Protelica, Inc. | Universal fibronectin Type III binding-domain libraries |
| JP2010538972A (ja) | 2007-08-20 | 2010-12-16 | ブリストル−マイヤーズ スクイブ カンパニー | 転移性癌の処置のためのｖｅｇｆｒ−２阻害剤の使用 |
| CN101932720A (zh) | 2007-10-31 | 2010-12-29 | 米迪缪尼有限公司 | 蛋白质支架 |
| WO2009073115A1 (en) | 2007-11-28 | 2009-06-11 | Bristol-Myers Squibb Company | Combination vegfr2 therapy with mtor inhibitors |
| JP2011507529A (ja) | 2007-12-19 | 2011-03-10 | セントコア・オーソ・バイオテツク・インコーポレーテツド | Ｍ１３ファージのｐＩＸへの融合を介する代替の足場タンパク質融合ファージ提示 |
| JP2011507543A (ja) | 2007-12-27 | 2011-03-10 | ノバルティス アーゲー | 改善されたフィブロネクチンベースの結合分子およびそれらの使用 |
| WO2009102431A1 (en) | 2008-02-12 | 2009-08-20 | Certusview Technologies, Llc | Searchable electronic records of underground facility locate marking operations |
| WO2009102421A2 (en) | 2008-02-14 | 2009-08-20 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind egfr |
| CN102076713B (zh) | 2008-05-02 | 2015-03-25 | 诺华股份有限公司 | 改进的基于纤连蛋白的结合分子及其用途 |
| EP2291399B1 (en) | 2008-05-22 | 2014-06-25 | Bristol-Myers Squibb Company | Multivalent fibronectin based scaffold domain proteins |
| DK2356269T3 (en) | 2008-10-31 | 2016-08-15 | Janssen Biotech Inc | FIBRONECTIN TYPE III DOMAIN-BASED SCAFFOLD COMPOSITIONS, PROCEDURES AND APPLICATIONS |
| US8415291B2 (en) | 2008-10-31 | 2013-04-09 | Centocor Ortho Biotech Inc. | Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses |
| TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子 |
| EA201100943A1 (ru) | 2008-12-16 | 2012-05-30 | Новартис Аг | Системы дрожжевого дисплея |
| WO2010093771A1 (en) | 2009-02-11 | 2010-08-19 | Bristol-Myers Squibb Company | Combination vegfr2 therapy with temozolomide |
| WO2010093627A2 (en) | 2009-02-12 | 2010-08-19 | Centocor Ortho Biotech Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
| US8067201B2 (en) | 2009-04-17 | 2011-11-29 | Bristol-Myers Squibb Company | Methods for protein refolding |
| WO2011020033A2 (en) | 2009-08-13 | 2011-02-17 | Massachusetts Institute Of Technology | Engineered proteins including mutant fibronectin domains |
| ES2860453T3 (es) | 2009-10-30 | 2021-10-05 | Novartis Ag | Bibliotecas universales del dominio de unión del lado inferior de la fibronectina de tipo III |
| WO2011051466A1 (en) | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
| US20110123545A1 (en) | 2009-11-24 | 2011-05-26 | Bristol-Myers Squibb Company | Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases |
| WO2011092233A1 (en) | 2010-01-29 | 2011-08-04 | Novartis Ag | Yeast mating to produce high-affinity combinations of fibronectin-based binders |
| CA2788972A1 (en) | 2010-02-12 | 2011-08-18 | University Of Rochester | Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies |
| JP2013520426A (ja) | 2010-02-18 | 2013-06-06 | ブリストル−マイヤーズ スクイブ カンパニー | Ｉｌ−２３に結合する、フィブロネクチンをベースとする足場ドメインタンパク質 |
| US9249508B2 (en) | 2010-03-14 | 2016-02-02 | Mark S. Braiman | Bromine-sensitized solar photolysis of carbon dioxide |
| SG10201505470QA (en) | 2010-04-13 | 2015-08-28 | Medimmune Llc | Trail r2-specific multimeric scaffolds |
| CN105175532B (zh) | 2010-04-13 | 2023-01-17 | 百时美施贵宝公司 | 结合pcsk9的基于纤连蛋白的支架域蛋白质 |
| WO2011137319A2 (en) | 2010-04-30 | 2011-11-03 | Centocor Ortho Biotech Inc. | Stabilized fibronectin domain compositions, methods and uses |
| TW201138808A (en) | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
| EP2576615B1 (en) | 2010-05-26 | 2016-03-30 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
| SG187225A1 (en) | 2010-07-30 | 2013-02-28 | Novartis Ag | Fibronectin cradle molecules and libraries thereof |
| JP2014504587A (ja) | 2010-12-22 | 2014-02-24 | ブリストル−マイヤーズ スクイブ カンパニー | Ｉｌ−２３に結合するフィブロネクチンをベースとするスカフォールドドメインタンパク質 |
| ES2942455T3 (es) | 2011-04-13 | 2023-06-01 | Bristol Myers Squibb Co | Proteínas de fusión Fc que comprenden enlazadores o disposiciones nuevos |
| US20140187488A1 (en) | 2011-05-17 | 2014-07-03 | Bristol-Myers Squibb Company | Methods for maintaining pegylation of polypeptides |
| EP2710382B1 (en) | 2011-05-17 | 2017-10-18 | Bristol-Myers Squibb Company | Improved methods for the selection of binding proteins |
| EP3540100B8 (en) | 2011-09-27 | 2022-11-02 | Janssen Biotech, Inc. | Fibronectin type iii repeat based protein scaffolds with alternative binding surfaces |
| ES2913840T3 (es) | 2014-03-20 | 2022-06-06 | Bristol Myers Squibb Co | Dominios de tipo III de fibronectina de unión a seroalbúmina |
| ES2781207T3 (es) * | 2015-09-23 | 2020-08-31 | Bristol Myers Squibb Co | Dominios de fibronectina de tipo iii de unión a seroalbúmina con velocidad de disociación rápida |
-
2011
- 2011-04-29 TW TW100115218A patent/TW201138808A/zh unknown
- 2011-05-02 US US13/098,851 patent/US8969289B2/en active Active
- 2011-05-03 AR ARP110101521A patent/AR081459A1/es unknown
- 2011-05-03 KR KR1020127031428A patent/KR101854931B1/ko active IP Right Grant
- 2011-05-03 EA EA201270775A patent/EA029334B1/ru not_active IP Right Cessation
- 2011-05-03 WO PCT/US2011/034998 patent/WO2011140086A2/en active Application Filing
- 2011-05-03 PE PE2012002119A patent/PE20130593A1/es not_active Application Discontinuation
- 2011-05-03 MX MX2015004831A patent/MX346557B/es unknown
- 2011-05-03 EP EP11730481.6A patent/EP2566888A2/en not_active Withdrawn
- 2011-05-03 CN CN201610756654.6A patent/CN107698682A/zh active Pending
- 2011-05-03 BR BR112012028162-3A patent/BR112012028162A2/pt not_active IP Right Cessation
- 2011-05-03 JP JP2013509178A patent/JP5876872B2/ja not_active Expired - Fee Related
- 2011-05-03 UY UY0001033366A patent/UY33366A/es not_active Application Discontinuation
- 2011-05-03 CA CA2798510A patent/CA2798510A1/en not_active Abandoned
- 2011-05-03 MX MX2012012800A patent/MX2012012800A/es active IP Right Grant
- 2011-05-03 CN CN201180033246.3A patent/CN103003301B/zh not_active Expired - Fee Related
- 2011-05-03 AU AU2011248273A patent/AU2011248273B2/en not_active Ceased
- 2011-05-03 SG SG10201503366XA patent/SG10201503366XA/en unknown
- 2011-05-03 SG SG2012080032A patent/SG185091A1/en unknown
-
2012
- 2012-10-30 TN TNP2012000518A patent/TN2012000518A1/en unknown
- 2012-10-31 CL CL2012003077A patent/CL2012003077A1/es unknown
- 2012-11-01 CO CO12197670A patent/CO6630173A2/es not_active Application Discontinuation
- 2012-11-01 IL IL222832A patent/IL222832A0/en active IP Right Grant
- 2012-11-30 ZA ZA2012/09091A patent/ZA201209091B/en unknown
-
2014
- 2014-11-25 US US14/552,823 patent/US9540424B2/en active Active
-
2015
- 2015-10-27 JP JP2015210912A patent/JP6219357B2/ja not_active Expired - Fee Related
-
2016
- 2016-11-29 US US15/363,724 patent/US10221438B2/en active Active
-
2017
- 2017-09-27 JP JP2017185708A patent/JP2018057368A/ja active Pending
-
2019
- 2019-01-10 US US16/244,921 patent/US10934572B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013531477A5 (ru) | ||
| JP2016052315A5 (ru) | ||
| AU2016262494B2 (en) | Expression constructs and methods of genetically engineering methylotrophic yeast | |
| JP2018532725A5 (ru) | ||
| JP2010068806A5 (ru) | ||
| JP7501356B2 (ja) | 融合タンパク質 | |
| JP2014506790A5 (ru) | ||
| JP2013534812A5 (ru) | ||
| JP2015525217A5 (ru) | ||
| JP2016000731A5 (ru) | ||
| FI2968461T3 (fi) | Fuusioproteiineja, jotka käsittävät pdgf:ää ja vegf:ää sitovia osia, ja menetelmiä niiden käyttämiseksi | |
| JP2013027391A5 (ru) | ||
| IL275497B (en) | Serum proteins with type iii fibronectin binding domains | |
| JP5868999B2 (ja) | 植物において組換えタンパク質を発現および精製するための費用効果が高い方法 | |
| RU2012122402A (ru) | Содержащие фактор фон виллебранда (vwf) препараты и способы, наборы и применения, связанные с ними | |
| JP2007513634A5 (ru) | ||
| JP2017512063A5 (ru) | ||
| JP2010273685A5 (ru) | ||
| JP2014510518A5 (ru) | ||
| JP2019514358A5 (ru) | ||
| JP2008519592A5 (ru) | ||
| JP2016530236A5 (ru) | ||
| JP2009513118A5 (ru) | ||
| JP2015524403A5 (ru) | ||
| US20190169229A1 (en) | Tangential flow filtration based protein refolding methods |